3SBio: Valuation Trap with Tell-Tale Signs of Corporate Governance Issues
3SBio is a leading pharmaceutical company in China. It has a dominant market share in two of its key products. Recently, the company's share price...
344 Views
Hong Kong Short Reporting - Insights from 12 July Data
We analyse the latest SFC data released last evening on short position reporting in Hong Kong for the week ended 12 July.Total short notional in...
412 Views
SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy
SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million. In this insight, we...
665 Views
Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs
Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...
718 Views
Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
711 Views